Search

Background: Steatotic Liver Disease is the most frequent chronic hepatic disease worldwide. Its prevalence is 30-38% and is associated with progression to steatohepatitis, fibrosis, cirrhosis, and Hepatocellular Carcinoma. A new terminology for this condition was recently published, classifying it into five groups., Aim: To evaluate the prevalence and the association of Steatotic Liver Disease with clinical and laboratory variables in a Preventive Medicine Unit., Methods: A cross-sectional and descriptive study. Patients over 18 years of age, with or without chronic diseases, who consulted the Preventive Medicine Unit of the Clínica Universidad de los Andes between February 2022 and March 2024 were included. Demographic, clinical, laboratory, and imaging data were collected. A hepatic steatosis diagnosis was made using abdominal ultrasound., Results: 4535 patients were included in the analysis; the mean age was 45.1 years, and 37.4% were women. 1214 patients (26.8%) met criteria for hepatic steatosis, who were older (p<0.001) and had a higher proportion of male sex than healthy patients (p<0.001). 94.3% met the criteria for hepatic steatosis associated with metabolic dysfunction; 3.2% met the criteria for metabolic dysfunction and alcohol consumption; 0.5% met the criteria for hepatic steatosis associated with alcohol consumption; and 2.0% met the criteria for cryptogenic hepatic steatosis or due to another cause., Conclusions: The prevalence of hepatic steatosis in our sample was 26.8%, with a significant difference between men and women. In 94.3% of cases, it was associated with metabolic dysfunction.

Background: In Chile, organ allocation for liver transplantation (LT) in adults is prioritized according to the MELD-Na score. Exceptions such as Hepatocellular Carcinoma (HCC) and other non-HCC exceptions receive a score called Operational MELD score., Aim: To evaluate the effectiveness of the MELD-Na score and the operational MELD score as a prioritization system for LT in Chile., Material and Methods: Retrospective analysis of the waiting list (WL) of adult candidates (≥ 15 years) for elective LT in Chile from 2011 to 2017. The probability of leaving the WL, defined by death or contraindication for LT was compared in three groups: 1) Cirrhotic patients prioritized according to their real MELD-Na score (CPM), 2) HCC and 3) other non-HCC exceptions., Results: We analyzed 730 candidates for LT, with a median age of 57 years, 431 (56%) were men. In the study period, 352 LT were performed (48%). The annual exit rate was significantly higher in the CPM group (45.5%) compared to HCC (33.1%) and non-HCC (29.3%), (p < 0.001). Post LT survival was 86% at 1 year and 85% at 5 years, without significant differences between groups. In the CPM group, post-transplant survival was significantly lower (p < 0.05) in patients with MELD-Na ≥ 30 at transplant (81% per year) compared to patients with patients with MELD-Na < 30 (91% per year)., Conclusions: MELD-Na score can discriminate very well patients who have a higher risk of death in the short and medium term. However, the assignment of operational scores for situations of exception produces inequities in the allocation of organs for LT and must therefore be carefully adjusted.

Liver involvement occurs in 0.2 to 3% of patients with syphilis. We report three patients with liver involvement in syphilis. A 52-year-old male presenting with erythema and malaise. Laboratory showed a gamma glutamyl transpeptidase (GGT) of 853 u/l, alkaline phosphatases of 1,010 U/L and VDRL was positive. Treatment with penicillin resolved the skin problem and normalized liver enzymes. A HIV positive 30-year-old male in peritoneal dialysis presenting with itching, malaise and markedly elevated GGT and alkaline phosphatases. VDRL was positive. He was treated with penicillin with remission of symptoms and enzyme normalization. A 43-year-old male presenting with erythema, malaise, arthralgias and elevated GGT and alkaline phosphatases. VDRL was positive and treatment with penicillin reverted symptoms and laboratory abnormalities.

Reported seroprevalence of hepatitis E virus (HEV) in developed countries is between 0.3-53%. Published data relies on the assays used and its technical performance. Sensitivity on new available tests has improved, which has changed HEV seroprevalence around the world. We re-evaluated retrospectively, 178 serum samples of patients with previous anti HEV IgG determination between 2009 and 2012. Initial analysis was performed with ELISA kit Genelabs (Singapore), with 7.3% positivity. The reevaluation was done with ELISA kit AccuDiag TM HEV-IgG (Diagnostic Automation, United States), with reported sensitivity and specificity over 99.8%. With the new assay, 32.6% positive samples were found, significantly greater to the previous result (p<0.001) (4.5 times more). There were no differences in gender but a significant association between age and HEV IgG seropositivity was found (p<0.001). This suggests that previous testing might have underestimated HEV seroprevalence in Chile, which should be reevaluated using the new available test.